Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

Results Exceeded Expectations

Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.

Encouraging early safety and biomarker data from uniQure’s gene therapy candidate, AMT-130, for Huntington’s disease have lifted hopes of progress against the disease.

The readout from 10 patients in the low-dose cohort of an ongoing Phase I/II trial in patients with early-stage Huntington’s disease showed no serious adverse events linked to the therapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

02 Jun 2025

• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

02 Jun 2025

• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.